BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brown AN, Liu L, Rodriquez JL, Zhao L, Schuster L, Li E, Wang GP, Neely MN, Yamada W, Drusano GL. Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV). Sci Rep 2017;7:14421. [PMID: 29089577 DOI: 10.1038/s41598-017-15007-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Ohsaki E, Suwanmanee Y, Ueda K. Chronic Hepatitis B Treatment Strategies Using Polymerase Inhibitor-Based Combination Therapy. Viruses 2021;13:1691. [PMID: 34578273 DOI: 10.3390/v13091691] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wang GP, Schnell GL, Kort JJ, Sidhu GS, Schuster L, Tripathi RL, Larsen L, Michael LC, Bergquist K, Magee A, Patel CB, Whitlock JA, Tamashiro R, Peter JA, Fried MW, Nelson DR. Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir. J Hepatol 2021:S0168-8278(21)00339-1. [PMID: 34023351 DOI: 10.1016/j.jhep.2021.04.057] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Alexander P, Dobrovolny HM. Treatment of Respiratory Viral Coinfections. Epidemiologia 2022;3:81-96. [DOI: 10.3390/epidemiologia3010008] [Reference Citation Analysis]
4 Drusano GL, Neely MN, Kim S, Yamada WM, Schmidt S, Duncanson B, Nole J, Mtchedlidze N, Peloquin CA, Louie A. Building Optimal Three-Drug Combination Chemotherapy Regimens. Antimicrob Agents Chemother 2020;64:e01610-20. [PMID: 32900682 DOI: 10.1128/AAC.01610-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]